Briacell Therap (NASDAQ:BCTX) Shares Up 0.3% – Time to Buy?

Briacell Therap (NASDAQ:BCTX) traded up 0.3% during trading on Monday . The company traded as high as $3.15 and last traded at $3.09. 91,575 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 303,369 shares. The stock had previously closed at $3.08.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Briacell Therap has an average rating of “Sell”.

Briacell Therap Stock Up 0.3%

The stock’s 50 day moving average is $3.91 and its two-hundred day moving average is $5.44. The company has a market capitalization of $26.88 million, a PE ratio of -0.13 and a beta of 1.21.

Briacell Therap (NASDAQ:BCTX) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($2.58) earnings per share for the quarter.

Institutional Trading of Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC acquired a new position in Briacell Therap (NASDAQ:BCTX) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap at the end of the most recent reporting period. 15.42% of the stock is owned by institutional investors.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.